

Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study

Jeong-Hoon Lim^{1,¶}, Jang-Hee Cho^{1,¶}, Yena Jeon², Ji Hye Kim¹, Ga Young Lee¹, Soojee Jeon¹, Hee Won Noh¹, Yong-Hoon Lee³, Jaehee Lee³, Hyun-Ha Chang⁴, Hee-Yeon Jung¹, Ji-Young Choi¹, Sun-Hee Park¹, Chan-Duck Kim¹, Yong-Lim Kim¹, and Shin-Woo Kim^{1,*}

¹Division of Nephrology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea

²Department of Statistics, Kyungpook National University, Daegu, South Korea

³Division of Pulmonology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea

⁴Division of Infectious Disease, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea

Supplementary Information Listing:

Supplementary Table S1, and Table S2

*Corresponding author:

Shin-Woo Kim, M.D, PhD

Professor

Division of Infectious Disease, Department of Internal Medicine,

Kyungpook National University School of Medicine,

Dongdeok-ro 130, Daegu, 41944, South Korea

Tel: +82-53-200-6525

Fax: +82-53-426-2046

E-mail: ksw2kms@knu.ac.kr

Supplementary Table S1. Associated factors of in-hospital mortality in the Cox proportional hazard model classified by doses of ACE-I or ARB

Variables	Model 1 [†]		Model 2 [‡]		Model 3 [§]	
	aHR (95% CI)	<i>P</i> value	aHR (95% CI)	<i>P</i> value	aHR (95% CI)	<i>P</i> value
ACE-I/ARB medication						
None	Reference		Reference		Reference	
Low-dose	2.09 (0.92–4.73)	0.078	1.92 (0.85–4.36)	0.119	1.67 (0.72–3.88)	0.234
High-dose	3.28 (1.32–8.15)	0.010	3.25 (1.30–8.10)	0.011	3.51 (1.39–8.88)	0.008
Age	1.82 (1.34–2.48)	<0.001	1.59 (1.16–2.18)	0.004	1.53 (1.11–2.13)	0.010
CCI			1.23 (1.04–1.45)	0.013	1.25 (1.06–1.48)	0.009
WBC count					1.07 (0.97–1.17)	0.177

[†]Model 1: adjusted for age; [‡]model 2: adjusted for model 1 plus CCI; [§]model 3: adjusted for model 2 plus WBC count.

aHR, adjusted hazard ratio; *CI*, confidence interval; *CCI*, Charlson Comorbidity Index; *WBC*, white blood cell.

Supplementary Table S2. Associated factors for serious complications in the multivariate logistic regression analysis classified by doses of ACE-I or ARB

Variables	ARDS		AKI	
	Adjusted OR (95% CI)	<i>P</i> value	Adjusted OR (95% CI)	<i>P</i> value
ACE-I/ARB				
medication				
None	Reference		Reference	
Low-dose	1.55 (0.50–4.76)	0.446	2.38 (0.76–7.46)	0.135
High-dose	6.80 (1.51–30.70)	0.013	2.60 (1.08–6.28)	0.034
Age	1.34 (0.93–1.93)	0.531	1.04 (0.70–1.54)	0.844
CCI	1.11 (0.88–1.40)	0.382	1.15 (0.91–1.45)	0.235
WBC count	1.17 (1.03–1.33)	0.018	1.05 (0.91–1.20)	0.520

ARDS, acute respiratory distress syndrome; *AKI*, acute kidney injury; *CI*, confidence interval;

CCI, Charlson Comorbidity Index; *OR*, odds ratio; *WBC*, white blood cell.